AU2001238677A1 - Method for preparing anti-mif antibodies - Google Patents

Method for preparing anti-mif antibodies

Info

Publication number
AU2001238677A1
AU2001238677A1 AU2001238677A AU3867701A AU2001238677A1 AU 2001238677 A1 AU2001238677 A1 AU 2001238677A1 AU 2001238677 A AU2001238677 A AU 2001238677A AU 3867701 A AU3867701 A AU 3867701A AU 2001238677 A1 AU2001238677 A1 AU 2001238677A1
Authority
AU
Australia
Prior art keywords
preparing anti
mif antibodies
mif
antibodies
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001238677A
Inventor
Nabil Hanna
William S. Kloetzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idec Pharmaceuticals Corp
Original Assignee
Idec Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharmaceuticals Corp filed Critical Idec Pharmaceuticals Corp
Publication of AU2001238677A1 publication Critical patent/AU2001238677A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
AU2001238677A 2000-02-28 2001-02-26 Method for preparing anti-mif antibodies Abandoned AU2001238677A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18539000P 2000-02-28 2000-02-28
US60185390 2000-02-28
US23362500P 2000-09-18 2000-09-18
US60233625 2000-09-18
PCT/US2001/005933 WO2001064749A2 (en) 2000-02-28 2001-02-26 Method for preparing anti-mif antibodies

Publications (1)

Publication Number Publication Date
AU2001238677A1 true AU2001238677A1 (en) 2001-09-12

Family

ID=26881101

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001238677A Abandoned AU2001238677A1 (en) 2000-02-28 2001-02-26 Method for preparing anti-mif antibodies

Country Status (3)

Country Link
US (2) US20030235584A1 (en)
AU (1) AU2001238677A1 (en)
WO (1) WO2001064749A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080407A (en) * 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF
DE19957065B4 (en) * 1999-11-26 2005-01-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Screening procedure for drugs
WO2002051438A2 (en) 2000-12-22 2002-07-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (rgm) and its modulators
US7361474B2 (en) * 2003-02-24 2008-04-22 United States Of America As Represented By The Department Of Veterans Affairs Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer
US20050202010A1 (en) * 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
WO2005094338A2 (en) * 2004-03-29 2005-10-13 North Shore-Long Island Jewish Research Institute Treatment of type 1 diabetes with inhibitors of macrophage migration inhibitory factor
US7555387B2 (en) * 2005-01-28 2009-06-30 Orbitz, L.L.C. System and method for providing travel related product information on an interactive display having neighborhood categories
CN101277974A (en) 2005-09-30 2008-10-01 阿伯特有限及两合公司 Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
US20100047171A1 (en) * 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
CN100457895C (en) * 2006-05-24 2009-02-04 中国科学院生物物理研究所 Rat antihuman macrephage migration inhibiting factor monoclone antibody and its application
AU2008333985B2 (en) 2007-11-30 2015-02-05 Kalobios Pharmaceuticals, Inc. Antibodies to the PcrV antigen of pseudomonas aeruginosa
CA2711029A1 (en) * 2008-01-04 2009-07-16 Baxter Healthcare S.A. Anti mif antibodies
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
MX2012006560A (en) 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration.
ES2649155T3 (en) 2010-08-23 2018-01-10 Board Of Regents, The University Of Texas System Anti-OX40 antibodies and procedures for their use
EP3081651A1 (en) * 2010-11-24 2016-10-19 Yale University Compositions and methods for diagnosing and treating diseases and disorders associated with d-dt
EP3604339B1 (en) 2011-01-14 2021-03-10 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
EP2731970B1 (en) 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
WO2013050453A1 (en) 2011-10-07 2013-04-11 Baxter Healthcare S.A. Oxmif as a diagnostic marker
WO2013050457A1 (en) 2011-10-07 2013-04-11 Baxter Healthcare S.A. Characterization of cho-mif gene and protein, and use thereof
RS57603B1 (en) 2012-01-27 2018-11-30 Abbvie Deutschland Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
AU2013203957B9 (en) * 2012-04-16 2015-10-15 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Glucocorticoids
AU2013202693B2 (en) * 2012-04-16 2015-01-22 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
CN104334173B (en) 2012-05-01 2017-05-03 特兰斯拉图姆医学公司 Methods for treating and diagnosing blinding eye diseases
KR20150029017A (en) * 2012-07-10 2015-03-17 박스터 헬쓰케어 에스에이 Anti-mif immunohistochemistry
EP2929348B1 (en) 2012-12-07 2017-05-10 Baxalta GmbH Anti-mif antibody cell migration assay
AU2013408259B2 (en) * 2013-12-20 2020-05-21 Development Center For Biotechnology Alpha-enolase specific antibodies and methods of uses in cancer therapy
US9382331B2 (en) 2013-12-27 2016-07-05 Development Center For Biotechnology Alpha-enolase specific antibodies and methods of uses in cancer therapy
AU2015206178A1 (en) 2014-01-03 2016-07-07 Baxalta GmbH Anti-MIF immunohistochemistry
WO2016005004A1 (en) * 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
EP3277718B1 (en) 2015-03-31 2021-03-24 Baxalta GmbH Dosage regimen for anti-mif antibodies
EP3298039A1 (en) 2015-05-18 2018-03-28 Baxalta GmbH Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras
WO2017117384A1 (en) 2015-12-31 2017-07-06 Development Center For Biotechnology Anti-vegfr antibody and uses thereof
EP3402520A4 (en) 2016-01-14 2019-01-02 BPS Bioscience, Inc. Anti-pd-1 antibodies and uses thereof
CA3029332A1 (en) 2016-07-01 2018-01-04 Ludwig Institute For Cancer Research Ltd Methods and compositions for pdgf-cc inhibition
WO2018050833A1 (en) * 2016-09-15 2018-03-22 Ablynx Nv Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
KR20200015921A (en) * 2017-07-03 2020-02-13 재단법인 생물기술개발중심 Anti-VEGFR Antibodies and Uses thereof
WO2019200181A1 (en) 2018-04-11 2019-10-17 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
EP3807644A4 (en) * 2018-06-12 2022-07-06 Angiex, Inc. Antibody-oligonucleotide conjugates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0672158B2 (en) * 1984-05-24 1994-09-14 チバ−ガイギ− アクチエンゲゼルシヤフト Purified human macrophage migration inhibitory factor
US6080407A (en) * 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF

Also Published As

Publication number Publication date
WO2001064749A2 (en) 2001-09-07
US20060191024A1 (en) 2006-08-24
WO2001064749A3 (en) 2002-05-02
US20030235584A1 (en) 2003-12-25
US7294753B2 (en) 2007-11-13

Similar Documents

Publication Publication Date Title
AU2001238677A1 (en) Method for preparing anti-mif antibodies
AU2001252588A1 (en) Method for preparing microsphere
AU2002357049A1 (en) Methods for preparing 0-desmethylvenlafaxine
AU2001240115A1 (en) Method for the preparation of tetrahydrobenzothiepines
AU2001295611A1 (en) Multipressure method for producing ammonia
AU2002231135A1 (en) Method for forming complex ceramic shapes
AU2001291882A1 (en) Method for producing polyisobutylphenols
AU2001278423A1 (en) Method for producing aldehydes
AU2001239243A1 (en) Method for producing nanosuspensions
AU2406001A (en) Method for preparing glass-ceramic
EP1298117A3 (en) Method for preparing bromofluorenes
AU2001231920A1 (en) Method for preparing alpha-halogenated ketones
AU2002222604A1 (en) Process for preparing substance GM-95
AU2001268981A1 (en) Method for producing 2-chloro-5-chloromethyl-1,3-thiazole
AU2002231187A1 (en) Method for synthesizing diamond
AU6898101A (en) Method for producing 2-chloro-5-chloromethyl-1,3-thiazole
AU2002220757A1 (en) Method for obtaining azaerythromycin
AU2002212224A1 (en) Method for producing delta1-pyrrolines
AU4663601A (en) Method for preparing 9-deoxo-8a-aza-(8a-alkyl)-8a-homoerythromycin derivativesfrom 9-deoxo-9(z)-hydroxyiminoerythromycin
AU2001262147A1 (en) Method for producing 4-bromo- and 4-chloro-2-nitro-1-trifluoromethoxybenzene
AU2002241271A1 (en) Method for preparing 7-quinolinyl-3,5-dihydroxyhept-6-enoate
AU2001272448A1 (en) Method for producing dna-arrays
HUP0401401A3 (en) Method for preparing 7-quinolinyl-3,5-dihydroxyhept-6-enoate
AU2001295042A1 (en) Anti-stilbene antibodies
AU2001274984A1 (en) An improved method for the preparation of hexafluoroacetone